Skip to main content

Clinical Outcomes

For more than 20 years, through clinical trials, registries and site-reported use, the GORE® TAG® Device family has proven to be safe, effective and durable, earning the trust of physicians worldwide.

Real-world1 treatment*

ANEURYSMS
97%
FREEDOM
from device-related
reintervention

TRANSECTION
ZERO
Type III endoleaks
Ruptures
Device fractures
Compressions
Conversions

TYPE B DISSECTION
100%
PROCEDURAL
SURVIVAL

 

97%
Dissection-
related-survival

Zero

ZERO
Observed fractures,
device compressions
and ruptures2

ZERO
Incidence of
migration shown in
aneurysm procedures3

See latest results

* GORE® TAG® Conformable Device.

† Endoleak requiring intervention. No endoleaks persisted past one month or required intervention.

  1. The GREAT Registry is a prospective, observational, multi-center registry to actively track Gore commercial aortic endovascular device performance and associated patient outcomes in global markets with 10 years of follow-up. Data June 2017. Through 2-year follow up. Aneurysm n=316; Transection n=53; Type B dissection n=269.
  2. Rates are based on physician experience as reported for 127 subjects in Europe within a 30-day follow-up period. European-Post Approval Registry: Observational Registry Characterizing the Performance and Feature Use of the GORE® TAG® Conformable Thoracic Stent Graft Featuring ACTIVE CONTROL System. (data on file 2017; W. L. Gore & Associates, Inc; Flagstaff, AZ.)
  3. Reported outcomes following 5-year-follow-up in FDA IDE clinical studies.